TransThera: TransThera Seeks Hong Kong IPO To Sustain Cancer Drug Research

Key Takeaways:The company's main revenue over the past decade came from a licensing-out deal with a South Korean company that lapsed last yearTransThera reached a valuation of 4.59 billion yuan after its D+ financing round in 2023 and is making its second attempt at a Hong Kong IPOBy Molly Wenread more